Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11621592 | 0.94 | L3MBTL1 (0.47) | L3MBTL1NPC1RAB9AALDH1A1CTBP2 | |
| SCHEMBL1479915 | 0.86 | NPC1 (0.55) | L3MBTL1NPC1RAB9AALDH1A1CTBP2 | |
| Chlorobenzene SCHEMBL27603194 | 0.86 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| 1,4-Dichlorobenzene SCHEMBL28257308 | 0.84 | TDP1 (0.56) | L3MBTL1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL7256785 | 0.83 | ALDH1A1 (0.49) | L3MBTL1NPC1RAB9AALDH1A1CTBP2 | |
| SCHEMBL7149195 | 0.82 | ALDH1A1 (0.52) | L3MBTL1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1538218 | 0.80 | ALDH1A1 (0.58) | L3MBTL1NPC1RAB9AALDH1A1CTBP2 | |
| SCHEMBL4632976 | 0.80 | NPC1 (0.50) | L3MBTL1NPC1RAB9AALDH1A1CTBP2 | |
| SCHEMBL5539303 | 0.80 | IAPP (0.40) | L3MBTL1ALDH1A1LMNAPOLBHPGD | |
| SCHEMBL17481548 | 0.80 | ALDH1A1 (0.59) | ALDH1A1LMNAPOLBMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104710256-A | Cheap and efficient synthesis method of alpha-hydroxyketone compound | UNIV BEIJING | 2015-06-17 | — | — | CN | claimed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-115505167-A | Cosolvent system, preparation method thereof and method for separating holocellulose | 武汉轻工大学 | 2022-12-23 | — | — | CN | disclosed |
| EP-3697763-A1 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2020-08-26 | — | — | EP | disclosed |
| WO-2020151738-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-30 | — | — | WO | disclosed |
| WO-2019076329-A9 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | TSAI GUOCHUAN EMIL (CN) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019076329-A1 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | TSAI GUOCHUAN EMIL (CN) | 2019-04-25 | — | — | WO | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-104710256-B | Cheap and efficient synthesis method of alpha-hydroxyketone compound | 北京大学 | 2017-03-22 | — | — | CN | disclosed |
| CN-104710256-A | Cheap and efficient synthesis method of alpha-hydroxyketone compound | UNIV BEIJING | 2015-06-17 | — | — | CN | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2220051-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | Syngenta Participations AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080314-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20070082923-A1 | Process for the synthesis of compounds for selectin inhibition | WYETH | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | L3MBTL1 748/4885NPC1 3565/4885RAB9A 1592/4885 |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | L3MBTL1 1003/4885NPC1 1587/4885RAB9A 2851/4885 |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | L3MBTL1 1425/4885NPC1 2957/4885RAB9A 458/4885 |
| US-20070082923-A1 | Process for the synthesis of compounds for selectin inhibition | SELP, SELE, SELL | L3MBTL1 1966/4885NPC1 3962/4885RAB9A 2894/4885 |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | HPN, PRSS1, SERPINB1 | L3MBTL1 3375/4885NPC1 613/4885RAB9A 3477/4885 |
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | C3AR1, CBR3, C1S | L3MBTL1 820/4885NPC1 2642/4885RAB9A 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.